President Donald Trump declared a 100 percent tariff on pharmaceutical imports effective October 1, 2025. The policy targets companies that refuse to establish manufacturing facilities within American borders. Industry experts believe this measure will not significantly affect Indian pharmaceutical exports to the United States. The tariff applies exclusively to branded and patented medications rather than generic alternatives.
Indian companies primarily export generic medicines, which constitute the majority of their American sales. The nation supplies approximately 45 percent of generic drugs and 15 percent of biosimilar medications consumed in the US market. India exported $8.7 billion worth of pharmaceutical products to America during fiscal year 2024. Major pharmaceutical companies experienced stock price declines of up to 5 percent following the announcement.
Indian companies primarily export generic medicines, which constitute the majority of their American sales. The nation supplies approximately 45 percent of generic drugs and 15 percent of biosimilar medications consumed in the US market. India exported $8.7 billion worth of pharmaceutical products to America during fiscal year 2024. Major pharmaceutical companies experienced stock price declines of up to 5 percent following the announcement.
